John O'Bryan to Cell Line, Tumor
This is a "connection" page, showing publications John O'Bryan has written about Cell Line, Tumor.
Connection Strength
0.391
-
Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Rep. 2022 02 08; 38(6):110322.
Score: 0.137
-
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis. Cancer Lett. 2015 Apr 10; 359(2):262-8.
Score: 0.084
-
Intersectin 1 is required for neuroblastoma tumorigenesis. Oncogene. 2012 Nov 15; 31(46):4828-34.
Score: 0.068
-
Neuroblastoma differentiation in?vivo excludes cranial tumors. Dev Cell. 2021 10 11; 56(19):2752-2764.e6.
Score: 0.033
-
Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nat Commun. 2021 05 11; 12(1):2656.
Score: 0.033
-
Silencing Intersectin 1 Slows Orthotopic Neuroblastoma Growth in Mice. J Pediatr Hematol Oncol. 2017 11; 39(8):e413-e418.
Score: 0.025
-
The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 2004 Feb 15; 64(4):1266-77.
Score: 0.010